甲磺酸羅哌卡因
| 中文名稱 | 甲磺酸羅哌卡因 |
|---|---|
| 中文同義詞 | N-(2,6-二甲基苯基)-1-丙基哌啶-2-甲酰胺甲磺酸鹽;甲磺酸羅哌卡因;N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺甲磺酸鹽;甲磺酸羅哌卡因854056-07-8;羅哌卡因甲磺酸鹽;甲磺酸羅哌卡因中間體;S-(-)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶甲酰胺甲磺酸鹽;(S)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶酰胺甲磺酸鹽 |
| 英文名稱 | Ropivacaine mesylate |
| 英文同義詞 | ROPIVACAINE MESYLATE;(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate;Ropivacaine Mesylate API;Ropivacaine mesylate (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate;Ropivacaine Mesylate Injection;Ropivacaine mesylate USP/EP/BP;(S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamidemethanesulfonate;TIANFUCHEM--854056-07-8--Ropivacaine mesylate in stock |
| CAS號(hào) | 854056-07-8 |
| 分子式 | C18H30N2O4S |
| 分子量 | 370.51 |
| EINECS號(hào) | 264-407-7 |
| 相關(guān)類別 | 麻醉劑類Narcotic;原料藥;醫(yī)藥 局麻藥;醫(yī)藥原料藥-科研原料;標(biāo)準(zhǔn)品;中藥對照品;藥物雜質(zhì)及中間體;醫(yī)藥原料藥;醫(yī)藥原料;科研原料 |
| Mol文件 | 854056-07-8.mol |
| 結(jié)構(gòu)式 |  |
甲磺酸羅哌卡因 性質(zhì)
| 儲(chǔ)存條件 | Store at -20°C |
|---|---|
| 形態(tài) | 固體 |
| 顏色 | 白色至米白色 |
| 水溶解性 | Water: 250 mg/mL (674.75 mM) |
圖1為甲磺酸羅哌卡因注射液
有關(guān)甲磺酸羅哌卡因的概述、藥理作用、臨床應(yīng)用是由Chemicalbook的丁紅編輯整理。（2015-12-02）1.局部麻醉。
2.硬膜外阻滯。
3.外周神經(jīng)阻滯。
4.蜘網(wǎng)膜下腔阻滯。
5.局部靜脈麻醉。
6.術(shù)后鎮(zhèn)痛。
7.產(chǎn)科麻醉。
8.分娩鎮(zhèn)痛。Ropivacaine mesylate 是一種有效的鈉通道 (sodium channel) 阻斷劑。Ropivacaine 通過可逆地抑制鈉離子內(nèi)流 (sodium ion influx) 從而引起神經(jīng)纖維脈沖傳導(dǎo)阻滯。Ropivacaine 也是一種 K2P (雙孔鉀通道) TREK-1 的抑制劑，在 COS-7 細(xì)胞膜上的 IC50 值為 402.7 μM。Ropivacaine 在動(dòng)物實(shí)驗(yàn)?zāi)Ｐ椭?，可用于局部麻醉和神?jīng)性疼痛的緩解。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300-400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/02/08 | HY-B0563C | 甲磺酸羅哌卡因 Ropivacaine mesylate | 854056-07-8 | 5 mg | 281元 |
| 2025/02/08 | HY-B0563C | 甲磺酸羅哌卡因 Ropivacaine mesylate | 854056-07-8 | 10mg | 450元 |